Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: melanotransferrin conjugated therapeutics - biOasis Technologies

Next Previous
Drug Profile

Research programme: melanotransferrin conjugated therapeutics - biOasis Technologies

Alternative Names: BT-2111; BT-2211; Herceptin®-BT2111; MTf-I2S; MTf-TZM; MTfp-I2S; MTfp-miRNA; MTfp-siRNA; MTfp-TZM; Transcend-Trastuzumab

Latest Information Update: 06 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator biOasis Technologies; University of British Columbia
  • Developer biOasis Technologies
  • Class Drug conjugates; Enzymes; Immunoconjugates; Metalloproteins; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Enzyme replacements; ERBB 2 receptor antagonists; Gene silencing; Immunomodulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease; Brain disorders; Breast cancer; Gangliosidoses; Glioblastoma; Lysosomal storage diseases; Mucopolysaccharidosis II

Most Recent Events

  • 20 Jun 2023 Discontinued - Preclinical for Alzheimer's disease in Canada (Parenteral) before June 2023
  • 20 Jun 2023 Discontinued - Preclinical for Brain disorders in Canada (Parenteral) before June 2023
  • 20 Jun 2023 Discontinued - Preclinical for Breast cancer (Metastatic disease) in Canada (Parenteral) before June 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top